|Public (Mercado Continuo: ALM-MC: ALM)|
|Founder||Antonio Gallardo Carreras|
|Headquarters||Ronda del General Mitre, 151
|Products||Ebastel, Monodox, Acticlate, Almogran, Tesavel & Efficib, Plusvent, Solaraze, Airtal, Decoderm, Cordran, Almax, Parapres, Balneum, Sativex, Cleboril, Monovo, Toctino, Constella, Actikerall.|
Number of employees
Almirall, S.A. (Ticker Bolsa de Madrid: ALM) is a pharmaceutical company, with headquarters in Barcelona, founded in 1943 and dedicated to providing medicines through its own R+D, agreements and alliances.
1943 Foundation of Laboratorios Almirall SA.
1992 Launch of the anti-inflammatory aceclofenac in Spain.
1993 Opening of the affiliate in Portugal.
1994 Opening of the new headquarters of Almirall in Barcelona.
1997 Merger of Almirall and Prodesfarma.
2002 Opening of the affiliate in Italy.
2003 Opening of the affiliate in Germany.
2007 Stock market flotation and trading on the continuous market in Spain. Acquisition of Hermal, European company specialized in dermatology, from Reckitt Benckiser. Acquisition of a portfolio of eight products from Shire plc.
2010 Opening of affiliate in the Nordic Countries.
2011 Almirall launches Actikerall prescribed for the local treatment of actinic keratosis.
2012 Opening of the affiliate in Canada. Launch of aclidinium, prescribed for chronic obstructive pulmonary disease (COPD), in Europe under the brand Eklira Genuair and Bretaris Genuair and in the USA under the brand Tudorza Pressair. Launch of Monovo for the treatment of inflammatory skin diseases such as psoriasis.
2014 Almirall transfers to Astrazeneca the rights of its respiratory franchise.
Almirall collaborates with various public and private entities, such as the Centro Superior de Investigaciones Científicas (CSIC), the Instituto de Investigación Biomédica and the Parc Científic de Barcelona in Spain. Highlighted among the international alliances are those with the Imperial College of London (United Kingdom) and the National Institute of Health (NIH) in the USA. Almirall participated in the creation of the Barcelona Respiratory Network Foundation. In Europe, the company has contributed in several projects with the Innovative Medicines Initiative (IMI).
The company has two R&D centres distributed in Spain and Germany. The R&D centre in Sant Feliu de Llobregat (Barcelona), houses the departments involved in all stages of R&D, as well as the development of new chemical entities. The Reinbek Centre of Excellence for Dermatology specializes in the development of new formulas for the treatment of skin diseases.
The company also has two production centres: two in Spain, the pharmaceutical plant in Sant Andreu de la Barca (Barcelona) and the pharmaceutical and chemical plant in Sant Celoni (Barcelona); and a pharmaceutical plant in Germany (Reinbek); as well as 15 affiliates in Germany, Austria, Belgium-Luxembourg, Canada, the USA, France, the Netherlands, Italy, Mexico, the Nordic Countries, Poland, Portugal, the United Kingdom-Ireland, Spain and Switzerland.
|Total revenue||€1002,1 MM||€873,1 MM||€900,2 MM||€825,5 MM|
|Net sales||€882,4 MM||€768,4 MM||€682,9 MM||€692,9 MM|
|% International sales||-||50%||60%||62%|
|% Sales of own medicines||-||-||59%||64%|
|Investment in R&D ||16,4% of net sales||18,8% of net sales||23,4% of net sales||18% of net sales|
|R&D Centres ||3||3||3||3|
|Acticlate||Doxycycline Hyclate||Severe Acne|
|Tesavel & Efficib||Sitagliptin and Sitagliptin + Metformin||Diabetes|
|Plusvent||Salmeterol / Fluticasone||COPD|
|Solaraze||Diclofenac sodium||Actinic keratosis|
|Cordran||Fludroxycortide||Inflammation and itching of the skin|
|Cleboril||Clebopride||Gastroesophageal reflux disease|
|Actikerall||5-Fluorouracil / Salicylic Acid||Actinic keratosis|
|Sativex||THC / Cannabidiol||Spasticity in Multiple Sclerosis|
|Toctino||Alitretinoin||Severe chronic hand eczema|
- Products «Products of Almirall S.A.» Retrieved 17th December 2014
- Almirall «What is the size of Almirall's overall workforce?» Retrieved 30 July 2014
- Almirall «History» Retrieved 18 December 2014
- Almirall «Almirall's annual reports» Retrieved 18 December 2014.
- Almirall «Almirall around the World» Retrieved 17th December 2014
- Partnering and Collaboration «Partnering and Collaboration» Retrieved 18 December 2014
- R&D in Key Therapeutic Areas «R&D in Key Therapeutic Areas» Retrieved 18 December 2014